Möchten Sie immer auf dem neuesten Stand bleiben?

Partnership with Cure HHT strengthens patient engagement and supports streamlined clinical trial executionHarmony-HHT Phase 1/2 trial activates first clinical site at Massachusetts General Hospital,...

CAMBRIDGE, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Atavistik Bio, a clinical-stage biotechnology company developing the next generation of selective allosteric therapeutics for the treatment of...

Atavistik Bio announces U.S. FDA clearance of investigational new drug application and Fast Track Designation for ATV-601 for the treatment of HHT.

Atavistik Bio closed a $40 million Series B extension for the advancement of its pipeline, bringing total round proceeds to $160 million.

Proceeds will support the advancement of Atavistik Bio’s oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) and the JAK2 V617F mutant-selective inhibitor program...

Atavistik Bio to present discovery of JAK2 V617F mutant-selective allosteric Inhibitors for the treatment of myeloproliferative neoplasms at ASH 2025.

Atavistik Bio today announced the expansion of its leadership team with the appointment of Susan Pandya, M.D., as Chief Medical Officer.

ATV-1601 is a first-in-class allosteric selective inhibitor of AKT1 E17KPan-AKT inhibitors offer limited efficacy for patients with AKT1 E17K-driven mutant tumors due to insufficient inhibition of the...

Atavistik Bio today announced the appointment of William Sellers, M.D. to its Scientific Advisory Board.

Atavistik Bio has entered into a research collaboration with Pfizer to accelerate the discovery of novel precision allosteric therapeutics.